Clinical Trials
11 trialsNCT05579366 2026-06-03
RAINFOL-01
Genmab
Phase 1/2 Recruiting
NCT07046923 2026-06-02
A Study of LY4175408 in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Recruiting
NCT01366144 2026-04-13
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT04644068 2026-02-19
PETRA
AstraZeneca
Phase 1/2 Active not recruiting
NCT06400472 2026-01-14
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
Eli Lilly and Company
Phase 1 Recruiting
NCT05867251 2025-11-19
Study of AVZO-021 in Patients With Advanced Solid Tumors
Avenzo Therapeutics, Inc.
Phase 1/2 Recruiting
NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT06297811 2024-03-07
Myeloprotection With Trilaciclib in Pan-cancer Population
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT02476955 2020-09-30
Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 1 Terminated
NCT01237067 2019-12-17
Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT02069158 2019-05-21
IOSI-NDU-001
Oncology Institute of Southern Switzerland
Phase 1 Completed